Cargando…

Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study

BACKGROUND: Until now, most of the research addressing long-term humoral responses in coronavirus disease 2019 (COVID-19) had only evaluated the serum titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgGs, without the assessment of the baseline antiviral clinical and immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Ruiz, Jiram, Lomelín-Gascón, Julieta, Vargas-Castro, Ana Sofía, Lira-Luna, Jaquelin, Pérez-Fragoso, Alfredo, Tapia-Conyer, Roberto, Nuñez-Aguirre, Miroslava, Alcalá-Carmona, Beatriz, Absalón-Aguilar, Abdiel, Maravillas-Montero, José Luis, Mejía-Domínguez, Nancy Raquel, Núñez-Álvarez, Carlos, Rull-Gabayet, Marina, Llorente, Luis, Romero-Ramírez, Sandra, Sosa-Hernández, Victor Andrés, Cervantes-Díaz, Rodrigo, Juárez-Vega, Guillermo, Meza-Sánchez, David Eduardo, Martínez-Juárez, Luis Alberto, Morales-Juárez, Linda, López-López, Lizeth Naomi, Negrete-Trujillo, José Adrián, Falcón-Lezama, Jorge Abelardo, Valdez-Vázquez, Rafael Ricardo, Gallardo-Rincón, Héctor, Gómez-Martín, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421299/
https://www.ncbi.nlm.nih.gov/pubmed/36045688
http://dx.doi.org/10.3389/fimmu.2022.943563
_version_ 1784777561923911680
author Torres-Ruiz, Jiram
Lomelín-Gascón, Julieta
Vargas-Castro, Ana Sofía
Lira-Luna, Jaquelin
Pérez-Fragoso, Alfredo
Tapia-Conyer, Roberto
Nuñez-Aguirre, Miroslava
Alcalá-Carmona, Beatriz
Absalón-Aguilar, Abdiel
Maravillas-Montero, José Luis
Mejía-Domínguez, Nancy Raquel
Núñez-Álvarez, Carlos
Rull-Gabayet, Marina
Llorente, Luis
Romero-Ramírez, Sandra
Sosa-Hernández, Victor Andrés
Cervantes-Díaz, Rodrigo
Juárez-Vega, Guillermo
Meza-Sánchez, David Eduardo
Martínez-Juárez, Luis Alberto
Morales-Juárez, Linda
López-López, Lizeth Naomi
Negrete-Trujillo, José Adrián
Falcón-Lezama, Jorge Abelardo
Valdez-Vázquez, Rafael Ricardo
Gallardo-Rincón, Héctor
Gómez-Martín, Diana
author_facet Torres-Ruiz, Jiram
Lomelín-Gascón, Julieta
Vargas-Castro, Ana Sofía
Lira-Luna, Jaquelin
Pérez-Fragoso, Alfredo
Tapia-Conyer, Roberto
Nuñez-Aguirre, Miroslava
Alcalá-Carmona, Beatriz
Absalón-Aguilar, Abdiel
Maravillas-Montero, José Luis
Mejía-Domínguez, Nancy Raquel
Núñez-Álvarez, Carlos
Rull-Gabayet, Marina
Llorente, Luis
Romero-Ramírez, Sandra
Sosa-Hernández, Victor Andrés
Cervantes-Díaz, Rodrigo
Juárez-Vega, Guillermo
Meza-Sánchez, David Eduardo
Martínez-Juárez, Luis Alberto
Morales-Juárez, Linda
López-López, Lizeth Naomi
Negrete-Trujillo, José Adrián
Falcón-Lezama, Jorge Abelardo
Valdez-Vázquez, Rafael Ricardo
Gallardo-Rincón, Héctor
Gómez-Martín, Diana
author_sort Torres-Ruiz, Jiram
collection PubMed
description BACKGROUND: Until now, most of the research addressing long-term humoral responses in coronavirus disease 2019 (COVID-19) had only evaluated the serum titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgGs, without the assessment of the baseline antiviral clinical and immune profile, which is the aim of this study and may be the key factor leading to a broad and sustained antibody response. METHODS: We included 103 patients with COVID-19. When the patients sought medical attention (baseline), a blood sample was drawn to perform immunophenotype of lymphocytes by flow cytometry. The patients were assessed 15 days after baseline and then every month until the third month, followed by a last visit 6 months after recruitment. We evaluated the anti-SARS-COV-2 IgG at all time points, and the serum levels of cytokines, chemokines, anti-cellular (AC) antibodies and neutrophil extracellular traps were also assessed during the follow-up. The primary outcome of the study was the presence of a sustained immune humoral response, defined as an anti-SARS-CoV-2 IgG titer >4.99 arbitrary units/mL in at least two consecutive measures. We used generalized lineal models to assess the features associated with this outcome and to assess the effect of the changes in the cytokines and chemokines throughout time on the development of a sustained humoral immune response. RESULTS: At baseline the features associated to a sustained immune humoral response were the diagnosis of critical disease, absolute number of lymphocytes, serum IP-10, IL-4, IL-2, regulatory T cells, CD8(+) T cells, and positive AC antibodies. Critical illness and the positivity of AC antibodies were associated with a sustained humoral immune response after 3 months, whilst critical illness and serum IL-13 were the explanatory variables after 6 months. CONCLUSION: A sustained immune humoral response is strongly related to critical COVID-19, which is characterized by the presence of AC antibodies, quantitative abnormalities in the T cell compartment, and the serum cytokines and chemokines during acute infection and throughout time.
format Online
Article
Text
id pubmed-9421299
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94212992022-08-30 Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study Torres-Ruiz, Jiram Lomelín-Gascón, Julieta Vargas-Castro, Ana Sofía Lira-Luna, Jaquelin Pérez-Fragoso, Alfredo Tapia-Conyer, Roberto Nuñez-Aguirre, Miroslava Alcalá-Carmona, Beatriz Absalón-Aguilar, Abdiel Maravillas-Montero, José Luis Mejía-Domínguez, Nancy Raquel Núñez-Álvarez, Carlos Rull-Gabayet, Marina Llorente, Luis Romero-Ramírez, Sandra Sosa-Hernández, Victor Andrés Cervantes-Díaz, Rodrigo Juárez-Vega, Guillermo Meza-Sánchez, David Eduardo Martínez-Juárez, Luis Alberto Morales-Juárez, Linda López-López, Lizeth Naomi Negrete-Trujillo, José Adrián Falcón-Lezama, Jorge Abelardo Valdez-Vázquez, Rafael Ricardo Gallardo-Rincón, Héctor Gómez-Martín, Diana Front Immunol Immunology BACKGROUND: Until now, most of the research addressing long-term humoral responses in coronavirus disease 2019 (COVID-19) had only evaluated the serum titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgGs, without the assessment of the baseline antiviral clinical and immune profile, which is the aim of this study and may be the key factor leading to a broad and sustained antibody response. METHODS: We included 103 patients with COVID-19. When the patients sought medical attention (baseline), a blood sample was drawn to perform immunophenotype of lymphocytes by flow cytometry. The patients were assessed 15 days after baseline and then every month until the third month, followed by a last visit 6 months after recruitment. We evaluated the anti-SARS-COV-2 IgG at all time points, and the serum levels of cytokines, chemokines, anti-cellular (AC) antibodies and neutrophil extracellular traps were also assessed during the follow-up. The primary outcome of the study was the presence of a sustained immune humoral response, defined as an anti-SARS-CoV-2 IgG titer >4.99 arbitrary units/mL in at least two consecutive measures. We used generalized lineal models to assess the features associated with this outcome and to assess the effect of the changes in the cytokines and chemokines throughout time on the development of a sustained humoral immune response. RESULTS: At baseline the features associated to a sustained immune humoral response were the diagnosis of critical disease, absolute number of lymphocytes, serum IP-10, IL-4, IL-2, regulatory T cells, CD8(+) T cells, and positive AC antibodies. Critical illness and the positivity of AC antibodies were associated with a sustained humoral immune response after 3 months, whilst critical illness and serum IL-13 were the explanatory variables after 6 months. CONCLUSION: A sustained immune humoral response is strongly related to critical COVID-19, which is characterized by the presence of AC antibodies, quantitative abnormalities in the T cell compartment, and the serum cytokines and chemokines during acute infection and throughout time. Frontiers Media S.A. 2022-08-15 /pmc/articles/PMC9421299/ /pubmed/36045688 http://dx.doi.org/10.3389/fimmu.2022.943563 Text en Copyright © 2022 Torres-Ruiz, Lomelín-Gascón, Vargas-Castro, Lira-Luna, Pérez-Fragoso, Tapia-Conyer, Nuñez-Aguirre, Alcalá-Carmona, Absalón-Aguilar, Maravillas-Montero, Mejía-Domínguez, Núñez-Álvarez, Rull-Gabayet, Llorente, Romero-Ramírez, Sosa-Hernández, Cervantes-Díaz, Juárez-Vega, Meza-Sánchez, Martínez-Juárez, Morales-Juárez, López-López, Negrete-Trujillo, Falcón-Lezama, Valdez-Vázquez, Gallardo-Rincón and Gómez-Martín https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Torres-Ruiz, Jiram
Lomelín-Gascón, Julieta
Vargas-Castro, Ana Sofía
Lira-Luna, Jaquelin
Pérez-Fragoso, Alfredo
Tapia-Conyer, Roberto
Nuñez-Aguirre, Miroslava
Alcalá-Carmona, Beatriz
Absalón-Aguilar, Abdiel
Maravillas-Montero, José Luis
Mejía-Domínguez, Nancy Raquel
Núñez-Álvarez, Carlos
Rull-Gabayet, Marina
Llorente, Luis
Romero-Ramírez, Sandra
Sosa-Hernández, Victor Andrés
Cervantes-Díaz, Rodrigo
Juárez-Vega, Guillermo
Meza-Sánchez, David Eduardo
Martínez-Juárez, Luis Alberto
Morales-Juárez, Linda
López-López, Lizeth Naomi
Negrete-Trujillo, José Adrián
Falcón-Lezama, Jorge Abelardo
Valdez-Vázquez, Rafael Ricardo
Gallardo-Rincón, Héctor
Gómez-Martín, Diana
Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
title Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
title_full Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
title_fullStr Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
title_full_unstemmed Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
title_short Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
title_sort clinical and immunological features associated to the development of a sustained immune humoral response in covid-19 patients: results from a cohort study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421299/
https://www.ncbi.nlm.nih.gov/pubmed/36045688
http://dx.doi.org/10.3389/fimmu.2022.943563
work_keys_str_mv AT torresruizjiram clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT lomelingasconjulieta clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT vargascastroanasofia clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT liralunajaquelin clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT perezfragosoalfredo clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT tapiaconyerroberto clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT nunezaguirremiroslava clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT alcalacarmonabeatriz clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT absalonaguilarabdiel clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT maravillasmonterojoseluis clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT mejiadomingueznancyraquel clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT nunezalvarezcarlos clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT rullgabayetmarina clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT llorenteluis clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT romeroramirezsandra clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT sosahernandezvictorandres clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT cervantesdiazrodrigo clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT juarezvegaguillermo clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT mezasanchezdavideduardo clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT martinezjuarezluisalberto clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT moralesjuarezlinda clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT lopezlopezlizethnaomi clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT negretetrujillojoseadrian clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT falconlezamajorgeabelardo clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT valdezvazquezrafaelricardo clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT gallardorinconhector clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy
AT gomezmartindiana clinicalandimmunologicalfeaturesassociatedtothedevelopmentofasustainedimmunehumoralresponseincovid19patientsresultsfromacohortstudy